Skip to main content

Veozah Side Effects

Generic name: fezolinetant

Medically reviewed by Drugs.com. Last updated on Jun 24, 2023.

Note: This document contains side effect information about fezolinetant. Some dosage forms listed on this page may not apply to the brand name Veozah.

Applies to fezolinetant: oral tablet.

Serious side effects of Veozah

Along with its needed effects, fezolinetant (the active ingredient contained in Veozah) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fezolinetant:

Less common

Other side effects of Veozah

Some side effects of fezolinetant may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to fezolinetant: oral tablet.

General

The most common adverse effects occurring in 2% of patients or greater included abdominal pain, diarrhea, insomnia, back pain, hot flush, and hepatic transaminase elevations.[Ref]

Cardiovascular

Common (1% to 10%): Hot flush[Ref]

Gastrointestinal

Common (1% to 10%): Abdominal pain including upper and lower, diarrhea[Ref]

Hepatic

Common (1% to 10%): Transaminase elevations[Ref]

Musculoskeletal

Common (1% to 10%): Back pain[Ref]

Psychiatric

Common (1% to 10%): Insomnia[Ref]

References

1. Product Information. Veozah (fezolinetant). Astellas Pharma US, Inc. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.